Please assess the completion status of the following clinical trial:

Trial Title: Risperidone and Zotepine in the Treatment of Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients may be included in the study if they meet all of the following criteria:DSM-IV-TR delirium (293.0 delirium due to general medical condition, 290.3 dementia with delirium 290.41, arteriosclerotic dementia with delirium 780.09delirium NOS. 292.8 substance-induced delirium( excluding alcohol and BZD)~* Age 18 to 85 year-old inpatients; either sex~* Patients are able to take Risperidone or Zotepine orally~Exclusion Criteria:~* Alcohol-induced delirium; delirium caused by seizures; Sedative, hypnotic or anxiolytic withdrawal delirium~* Patients with schizophrenia or bipolar disorder or being treated with antipsychotics~* Patients are mandatory to take parenteral treatments~* Patients are known to be allergic to Risperidone or Zotepine~* Women with pregnancy or during lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): zotepine , start from 50mg/day then titrate according to individual case
- 2 (Type: ACTIVE_COMPARATOR): Risperidone, start from 1mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).